Experimental in vitro dosimetry of .sup.223./sup.Ra and .sup.177./sup.Lu

0560657 - ÚJF 2023 RIV GB eng J - Článek v odborném periodiku
Ondrák, L. - Sommer, Marek - Štěpán, Václav - Davídková, Marie - Vlk, M. - Kundrát, Pavel - Kozempel, J.
Experimental in vitro dosimetry of ²²³Ra and ¹⁷⁷Lu.
Radiation Protection Dosimetry. Roč. 198, 9-11 (2022), s. 508-513. ISSN 0144-8420. E-ISSN 1742-3406
Institucionální podpora: RVO:61389005
Klíčová slova: targeteda alpha therapy * radiation dose * absorbed dose
Obor OECD: Inorganic and nuclear chemistry
Impakt faktor: 1, rok: 2022
Způsob publikování: Omezený přístup
https://doi.org/10.1093/rpd/ncac090

Targeted alpha therapy with radionuclides undergoing multiple alpha-particle decays is a promising method of nuclear medicine. To study the effectiveness of alpha versus beta emitters, survival of DU145 prostate cancer cells exposed to Ra-223 or Lu-177 was assessed. Per decay, the cells were much more sensitive to the alpha than beta emitter. However, per unit dose the sensitivities would be comparable, contrary to the well-known evidence, if the decay energy were deposited within the sample completely and homogeneously. Measurements by Timepix detectors showed about three times higher counts of alpha particles above than below the sample. After the first alpha decay of Ra-223 to Rn-219, this gas likely moves upwards and its subsequent three alpha decays occur in the upper part of the sample. Correct estimation of absorbed dose is a critical issue when analysing in vitro data and when translating their results to clinical applications.
Trvalý link: https://hdl.handle.net/11104/0333520